New data are available in the search for a new male contraceptive method. Safety, efficacy, and acceptability data from a phase II study of a hormonal male contraceptive, conducted at 10 sites in 7 countries between 2008 and 2012, were recently published in the Journal of Clinical Endocrinology and Metabolism. The investigational product was an intramuscular injection of norethisterone enanthate combined with testosterone undecanoate, given every 8 weeks. Even though the study was terminated early, it offers important information for the development of hormonal contraception for men.
ความคิดเห็น